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Items for this week’s EPI Update include: 
• Pertussis Update 
• Update on Lyme Disease in Iowa 
• Departing Message from Dr. Aileen Buckler, Deputy State Epidemiologist 
• HACCP Overview 
• Influenza Surveillance Assistance Needed 
• Protect Iowa Health Education Campaign 
• Meeting Announcement and Training Opportunities  
 
Pertussis Update 
The Iowa Department of Public Health continues to monitor pertussis activity across the 
state. It has been noted that there has been an increasing number of cases in infants 
younger than six months of age. We would like to bring your attention to the Centers for 
Disease Control and Prevention’s updated summary of oral macrolide (erythromycin, 
clarithromycin, azithromycin) treatment and prophylaxis for pertussis by age group 
(http://www.idph.state.ia.us/adper/common/pdf/immunization/pertussis_table.pdf). 
Because some texts are only updated every several years (Red Book, Vaccine 
Preventable Disease Manual), not all the information currently available is the same. The 
table of medications for pertussis represents the most current recommendation for 
pertussis treatment/prophylaxis. 
 
One of the important changes on the table is that for infants less than one month of age. 
The preferred drug is azithromycin 10mg/kg/day in a single daily dose for five days. 
 
Clinical studies have demonstrated that azithromycin has microbiologic effectiveness 
comparable with erythromycin for treatment of pertussis. Azithromycin has fewer and 
milder adverse events, achieves higher tissue concentration, has improved patient 
compliance, has fewer daily doses, and the treatment course is shorter. Limited data from 
small clinical trials are available that confirm the microbiologic effectiveness of this 
agent in infants less than six months of age with pertussis, who are likely to be partially 
or unimmunized and whose colonization is more likely to be prolonged compared with 
older, previously immunized individuals with pertussis. These studies report a decrease in 
adverse events with no increased risk of infantile hypertrophic pyloric stenosis (IHPS) in 
infants < 1 months of age that received azithromycin. 
 
For prophylaxis, the benefits of administering a macrolide should be weighed according 
to the risk of disease and complications versus the potential adverse effects of the drug. 
Because of severe and sometimes fatal pertussis-related complications in infants under 
six months of age, postexposure prophylaxis should be given. All infants <1 month of 
age who receives any macrolide should be monitored for the development of IHPS. 
 
Antimicrobial treatment should be initiated as soon as pertussis is suspected in a patient. 
Initiating treatment > three weeks after cough onset has limited benefit to the patient or 
contacts. However, treatment is recommended up to six weeks after cough onset in high-
risk cases and prophylaxis should be considered for high-risk contacts up to six weeks 
after exposure (infants less than 12 months of age are considered high-risk cases or 
contacts).  
 
TMP-SMZ may be used as an alternative agent in patients who are allergic to macrolides, 
who cannot tolerate macrolides or who are infected, rarely, with a macrolide-resistant 
strain of Bordetella pertussis. The recommended dose in children is trimethoprim eight 
mg/kg/day, sulfamethoxazole 40 mg/kg/day in two divided doses for 14 days. For adults, 
the recommended dose is trimethoprim 320 mg/day, sulfamethoxazole 1600 mg/day in 
two divided doses for 14 days. Because of the risk of kernicterus, TMP-SMZ should not 
be given to pregnant women, nursing mothers, premature neonates or infants < two 
months of age. 
 
Update on Lyme Disease in Iowa 
Although Lyme disease is mostly localized in the northeastern, mid-Atlantic and upper 
north central states, it also occurs in several counties in northwestern California and in 
some parts of Iowa. In 2002, there were 23,763 cases of Lyme disease reported to the 
Centers for Disease Control and Prevention (CDC) (MMWR 52(31):741-750). Of these 
cases, 95 percent were from the states of Connecticut, Delaware, Rhode Island, Maine, 
Maryland, Massachusetts, Minnesota, New Jersey, New Hampshire, New York, 
Pennsylvania and Wisconsin.  
 
During 2004, 49 cases of Lyme disease were reported in Iowa; of these, 35 (71 percent) 
occurred in eastern Iowa counties. Iowa’s Lyme disease cases for 2005 so far total 57 
cases, with 44 cases reported from eastern Iowa counties (77 percent). From ongoing tick 
surveillance from ISU Entomology, the human cases of Lyme disease correlate with 
where deer ticks predominantly live in our state – eastern Iowa. Historically, the 
percentage of deer ticks in Iowa estimated to be infected with the organism that causes 
Lyme disease (Borrelia burgdorferi) has remained at approximately eight to 10 percent.  
 
A person’s chances of being infected with the Lyme disease organism is usually less 
than three percent. Research has shown that an infected deer tick must be attached for 
more than 24 hours (typically 48 to 72 hours) to transmit the organism. Additionally, the 
nymph stage of deer ticks (pre-adults) is more likely to transmit the organism than adult 
deer ticks. Because feeding nymphs are rarely noticed due to their small size, they are 
more likely to feed for at least 48 to 72 hours. Approximately 75 percent of people with 
confirmed Lyme disease did not find a tick on them, nor do they recall having been 
bitten by a tick. 
Diagnosis of Lyme disease should be made after evaluation of a patient's clinical 
presentation and risk for exposure to infected ticks, and, if indicated, by the use of 
validated laboratory tests. The Food and Drug Administration has approved 70 serologic 
assays in the United States that healthcare providers can use to aid in the diagnosis of 
Lyme disease. Initial testing for a person who may have Lyme disease should be 
performed by an enzyme immunoassay (EIA) or immunofluorescent assay (IFA). 
Positive or equivocal EIA or IFA test results should be tested further by using a 
standardized Western immunoblot assay. Specimens negative by a sensitive EIA or 
IFA do not need further testing. CDC guidance on diagnostic testing for Lyme disease 
is available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5405a6.htm. 
Under most circumstances, treating a person who has only had a tick bite is NOT 
recommended. The Infectious Disease Society of America (IDSA) does not recommend 
giving antibiotics just because someone has been bitten by a tick. In addition, IDSA does 
not recommend testing deer ticks for Borrelia burgdorferi, except as a research tool. 
Treatment by a medical provider should not be based on the results of testing deer ticks, 
but rather on evaluation of the patient. The recommendation by CDC, IFDSA and 
IDPH for persons who find ticks attached to them is to watch for fever or a rash at the site 
of attachment for 30 days. If these symptoms occur, they should see their medical 
provider to be assessed for Lyme disease or one of the other diseases that can be 
transmitted by ticks (for example, human granulocytic ehrlichiosis, Rocky Mountain 
spotted fever or babesiosis). 
For the IDSA’s guidelines on treatment of Lyme disease, please go to:  
<http://www.journals.uchicago.edu/CID/journal/issues/v31nS1/000342/000342.web.pdf>
.  
CDC homepage for Lyme disease: 
http://www.cdc.gov/ncidod/dvbid/lyme/index.htm. 
 




Departing Message from Dr. Aileen Buckler, Deputy State Epidemiologist 
Friday, Sept. 16 will be my last day at the Iowa Department of Public Health. As some of 
you may know, my husband’s father has bladder cancer. Although he was diagnosed a 
couple of years ago, this spring, and particularly this summer, he has had a lot of 
complications and is not doing well. My husband and I have made the decision that we 
need to move back to Virginia so we can be more available to help and also so that our 
children can have the opportunity to get to know their grandfather while they still can. 
 
I am grateful for all the help that I received from everyone when I moved here, not only 
with finding my place in CADE, but also in Iowa. I appreciate the patience everyone had 
with me the first few months, and I feel like I have really grown in my abilities as an 
epidemiologist through working with everyone at the state and local levels. I was only 
here for a little over a year and did not get to meet everyone in the field, but all of the 
interactions I have had with those at the local health departments and in the medical 
community through the fall EPI Updates, outbreak investigations and all the other 
interesting diseases we have worked on have been rewarding. I could tell that everyone I 
worked with really cared about what they were doing to help Iowa become a healthier 
place. I have learned so much here and hope I will be able to use all the knowledge I 
gained in a future public health position. (For now I will be a stay-at-home mom to my 




Hazard Analysis and Critical Control Point, or HACCP (pronounced “hassip”) is a 
systematic approach to ensuring food safety through the application of a set of principles 
targeted at preventing hazards in a particular setting that could result in foodborne illness. 
HACCP involves seven principles: 
• Analyze hazards. Potential hazards associated with a food and measures to control 
those hazards are identified. The hazard could be biological, such as a microbe; 
chemical, such as a toxin; or physical, such as ground glass or metal fragments.  
• Identify critical control points. These are points in a food's production – from its 
raw state, through processing and shipping, to consumption by the consumer – at 
which the potential hazard can be controlled or eliminated. Examples are cooking, 
cooling, packaging and metal detection.  
• Establish preventive measures with critical limits for each control point. For a 
cooked food, for example, this might include setting the minimum cooking 
temperature and time required to ensure the elimination of any harmful microbes.  
• Establish procedures to monitor the critical control points. Such procedures 
might include determining how and by whom cooking time and temperature should 
be monitored and documented.  
• Establish corrective actions to be taken when monitoring shows that a critical 
limit has not been met – for example, reprocessing or disposing of food if the 
minimum cooking temperature is not met.  
• Establish procedures to verify that the system is working properly – for example, 
testing time-and-temperature recording devices to verify that a cooking unit is 
working properly. 
• Establish effective record keeping to document the HACCP system. This would 
include records of hazards and their control methods, the monitoring of safety 
requirements and action taken to correct potential problems. Each of these principles 
must be backed by sound scientific knowledge: for example, published 
microbiological studies on time and temperature factors for controlling foodborne 
pathogens.  
 
HACCP provides a scientific approach to identifying and preventing hazards from 
contaminating food. HACCP is applied in a large number of food manufacturing settings 
allowing government oversight through the review of records. This review enables 
investigators to see how well a firm is complying with food safety laws over a period of 
time, rather than at a particular instant during an onsite inspection. HACCP places the 
responsibility for ensuring food safety appropriately on the food manufacturer or 
distributor. A HACCP-based inspection process has become the focus of compliance 
inspections of retail facilities and its principles are utilized in the investigation of 
foodborne outbreaks to identify errors in food handling processes that may have resulted 
in contamination. 
 




Influenza Surveillance Assistance Needed 
Attention school nurses, long-term care facilities and childcare centers!!!  We need your 
help with influenza surveillance this season! 
 
CADE is currently seeking volunteers from schools, long term care facilities and 
childcare centers to track the number of attendees and absences/ill residents throughout 
the influenza season. Participants will be asked to report every week through an online 
survey. Entering information into the survey takes only a few minutes. Reporting the 
number of absences/ill due to influenza-like illness is optional. If you do not have 
Internet access, you will be able to report by phone.  
 
The data received will be used to determine the level and locations of influenza activity 
throughout the state. Influenza surveillance data also helps to determine vaccine efficacy 
and where disease prevention measures should be focused.  
 
For your efforts, the program epidemiologist will work to provide you with templates of 
educational materials for your facility and monthly, custom reports of activity in your 
facility. To request more information or volunteer for the program, contact Meghan 
Harris at mharris@idph.state.ia.us or 515-281-7134.  
 
 
Protect Iowa Health Education Campaign 
The Iowa Department of Public Health has developed a public education campaign, 
Protect Iowa Health, to encourage Iowans to prepare for public health emergencies. To 
obtain a copy of the guidebook call 1-866-339-7906, log onto 
www.protectiowahealth.org for a pdf. version or contact your local public health agency. 
Guidebooks are also available at county ISU Extension offices, Hy-Vee stores, 
participating U.S. Cellular stores and Casey’s General stores. The guidebook is currently 
available in English and Spanish. 
 
Meeting Announcement and Training Opportunities  
The brochure for the fall Epidemiology Updates is now online at the Iowa Department of 
Public Health’s website at: 
<http://www.idph.state.ia.us/common/pdf/conferences/disease_prevention_fall.pdf>. 
 
8th Annual Iowa HIV/AIDS Conference - October 11-12, 2005, the conference brochure 




Have a healthy and happy week!  
Center for Acute Disease Epidemiology  
Iowa Department of Public Health  
800-362-2736  
 
